ArticleRSC advances2025
Design, characterization, and
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Repurposing neurological drugs for brain cancer therapeutics: A systematic approach to identify charged molecules for affinity-based local drug delivery systems.International journal of pharmaceutics · 2025Pooled it
- Nanoencapsulation ofRSC advances · 2026Article
- Pathology-tailored nanotherapy via Galectin-3-targeted and triple-responsive nanoparticles enables multimodal therapy against aortic dissection.Journal of nanobiotechnology · 2026Article
- Cyclodextrin: Dual Functions as a Therapeutic Agent and Nanocarrier for Regulating Cholesterol Homeostasis in Atherosclerosis.Pharmaceutics · 2025Review
- Effect of Reaction Parameters on the Synthesis of Cyclodextrin-Based Nanostructured Polymers for Drug Delivery.Polymers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, a magnetic carboxymethylated β-cyclodextrin (Mag/CM-β-CD) was developed as a carrier system to assess its capability on drug delivery application by forming an inclusion complex with amantadine (Amn) as a drug model. The synthesized inclusion complex (Mag/CM-β-CD/Amn) was analyzed using various techniques, including FT-IR, XRD, BET, TGA, TEM, VSM, and DLS. The encapsulation efficiency and drug release study of Mag/CM-β-CD/Amn were adopted using the spectroscopic method. Furthermore, the kinetics of drug release by different mathematical models was studied. The cytotoxicity evaluation of Mag/CM-β-CD and Mag/CM-β-CD/Amn was studied using MTT assay against the HUVEC cell line. The TEM imaging showed a spherical morphology and average size of less than 25 nm for the drug complex. Mag/CM-β-CD showed high EE% by absorbing 81.51% of amantadine. Mag/CM-β-CD/Amn showed a pH-sensitive manner with a higher release rate at acidic pH. In addition, a kinetic study reveals that the release process followed the Fickian mechanism and was governed by diffusion. The MTT assay demonstrated low toxicity for the Mag/CM-β-CD/Amn complex in HUVEC cells, showing a cell viability of 57.13% at a concentration of 1000 μg mL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.